Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Welch & Forbes LLC

Welch & Forbes LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,637 shares of the medical research company’s stock after purchasing an additional 66 shares during the period. Welch & Forbes LLC’s holdings in Thermo Fisher Scientific were worth $46,517,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TMO. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Thermo Fisher Scientific by 26.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 3,883 shares of the medical research company’s stock valued at $2,061,000 after purchasing an additional 824 shares in the last quarter. Apollon Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 12.2% during the 4th quarter. Apollon Wealth Management LLC now owns 9,805 shares of the medical research company’s stock worth $5,204,000 after buying an additional 1,067 shares during the last quarter. Lincoln National Corp increased its holdings in shares of Thermo Fisher Scientific by 7.5% in the 4th quarter. Lincoln National Corp now owns 7,314 shares of the medical research company’s stock valued at $3,882,000 after acquiring an additional 512 shares during the last quarter. Fielder Capital Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $255,000. Finally, Machina Capital S.A.S. grew its position in shares of Thermo Fisher Scientific by 96.2% in the 4th quarter. Machina Capital S.A.S. now owns 3,924 shares of the medical research company’s stock valued at $2,083,000 after buying an additional 1,924 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Raymond James boosted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Price Performance

TMO traded up $1.16 during midday trading on Monday, reaching $573.54. 1,140,681 shares of the company’s stock were exchanged, compared to its average volume of 1,544,948. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business’s 50-day moving average price is $575.59 and its 200 day moving average price is $534.36. The stock has a market capitalization of $218.93 billion, a PE ratio of 36.79, a P/E/G ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,277 shares of company stock valued at $35,373,364. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.